24 November 2026

Botanix allowed additional U.S. patent claims covering sofpironium bromide applicator system and method of use

Key highlights

- Additional U.S. patent claims allowed covering the proprietary applicator technology used with sofpironium bromide (*Sofdra*®) for the treatment of primary axillary hyperhidrosis.
- Allowed claims protect the applicator device, treatment methods and integrated applicator-dispenser system, further strengthening Botanix's comprehensive intellectual property portfolio.
- Additional protection granted for methods of treating hyperhidrosis, using the patented dispensing container for dispensing sofpironium bromide onto the applicator and applying the medication directly to affected skin.
- New patent protection extends to use of the applicator technology with gel, lotion, ointment and cream formulations of sofpironium bromide.
- Once issued, the newly allowed applicator claims will supplement Botanix's existing intellectual property portfolio, which provides protection for the commercial drug substance into May 2040.

PHOENIX USA – 24 November 2026: Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, "Botanix" or "the Company"), today announced that the United States Patent and Trademark Office (USPTO) has allowed additional patent claims directed to the proprietary applicator technology used with sofpironium bromide for the treatment of primary axillary hyperhidrosis. The USPTO's allowance indicates that the patent examiner has determined the claims are allowable and intends to grant the patent after customary issue-fee and administrative requirements are met.

The newly allowed claims cover Botanix's proprietary applicator-cap design, integrated dispensing system and methods for administering sofpironium bromide to treat hyperhidrosis.

The method-of-use claims provide additional intellectual property protection around the dispensing and application of sofpironium bromide for treatment of hyperhidrosis using Botanix's proprietary delivery platform, complementing existing formulation patent protection.

The expanded patent estate further reinforces the differentiation and long-term protection of *Sofdra*® (sofpironium) topical gel, 12.45%, approved in the United States for treatment of primary axillary hyperhidrosis in adults and children aged nine years and older.

The allowed claims include protection for:

- A unitary applicator and cap configured for use with a dispensing container containing a pharmaceutical preparation comprising sofpironium bromide
- The design and structural features of the applicator, including a rigid reservoir area, peripheral application ridge, gripping features, and attachment mechanism
- Applicator systems comprising both the metered-dose dispensing container and the applicator-cap assembly

- Methods of treating excessive sweating (hyperhidrosis) through dispensing sofpironium bromide onto the applicator reservoir and subsequently applying the formulation to the patient's skin
- Additional embodiments including overcap configurations and applicator attachment features.

The claims cover applicator systems for sofpironium bromide formulations in gel, lotion, ointment, or cream, and metered-dose pump dispensers configured to deliver accurate therapeutic doses.

Botanix Chief Executive Officer Dr Howie McKibbon said:

'These additional allowed claims further strengthen Botanix's intellectual property estate surrounding the administration of sofpironium bromide and provide protection for key elements of the user-friendly applicator technology that supports treatment of hyperhidrosis patients.

'The allowed claims extend protection across the applicator device, treatment method and integrated delivery system, reinforcing the Company's long-term competitive position.'

Once issued, the newly allowed applicator claims are expected to supplement Botanix's existing intellectual property portfolio, which already includes issued patents providing protection for the commercial drug substance into May 2040.

Botanix will continue to pursue additional patent protection opportunities.

Release authorised by

Vince Ippolito
Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: www.botanixpharma.com

For more information, please contact:

General enquiries
Botanix Pharmaceuticals
Corporate Communications
P: +61 8 6285 0083
info@botanixpharma.com

Investor and Media Relations
Jane Morgan Management
Wilamina Russo
P: +61 450 646 609
wr@janemorganmanagement.com.au

Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" "outlook", "guidance" and other similar expressions

and include, but are not limited to, plans and prospects for the Company, the Company's strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra* and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.